[go: up one dir, main page]

CL2022001079A1 - Métodos y composiciones para el tratamiento del síndrome de rett - Google Patents

Métodos y composiciones para el tratamiento del síndrome de rett

Info

Publication number
CL2022001079A1
CL2022001079A1 CL2022001079A CL2022001079A CL2022001079A1 CL 2022001079 A1 CL2022001079 A1 CL 2022001079A1 CL 2022001079 A CL2022001079 A CL 2022001079A CL 2022001079 A CL2022001079 A CL 2022001079A CL 2022001079 A1 CL2022001079 A1 CL 2022001079A1
Authority
CL
Chile
Prior art keywords
methods
rett syndrome
compositions
treatment
trofinetide
Prior art date
Application number
CL2022001079A
Other languages
English (en)
Inventor
Lawrence Irwin Glass
Mon Darwish
James M Youakim
Nancy Elizabeth Jones
Sean Paul Oosterholt
Oscar Della Pasqua
Original Assignee
Neuren Pharmaceuticals Ltd
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd, Acadia Pharm Inc filed Critical Neuren Pharmaceuticals Ltd
Publication of CL2022001079A1 publication Critical patent/CL2022001079A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)

Abstract

En la presente se divulgan métodos de tratamiento del síndrome de Rett que comprenden administrar trofinetide a un sujeto que lo necesita en los que se proporciona una dosificación que puede reducir o evitar una subexposición, p. ej., en sujetos de peso corporal bajo, y/o proporcionar otros beneficios.
CL2022001079A 2019-10-28 2022-04-28 Métodos y composiciones para el tratamiento del síndrome de rett CL2022001079A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US202063031201P 2020-05-28 2020-05-28

Publications (1)

Publication Number Publication Date
CL2022001079A1 true CL2022001079A1 (es) 2023-04-21

Family

ID=75715568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001079A CL2022001079A1 (es) 2019-10-28 2022-04-28 Métodos y composiciones para el tratamiento del síndrome de rett

Country Status (14)

Country Link
US (1) US20220339138A1 (es)
EP (1) EP4051308A4 (es)
JP (2) JP2022553888A (es)
KR (1) KR20220106982A (es)
CN (1) CN115335071A (es)
AU (1) AU2020376801A1 (es)
BR (1) BR112022008095A2 (es)
CA (1) CA3156680A1 (es)
CL (1) CL2022001079A1 (es)
CO (1) CO2022007501A2 (es)
IL (1) IL292617B1 (es)
MX (1) MX2022004785A (es)
TW (1) TW202116300A (es)
WO (1) WO2021086892A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240035406A (ko) * 2021-07-12 2024-03-15 아카디아 파마슈티칼스 인코포레이티드 트로피네타이드의 결정형
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
PT2667715T (pt) * 2011-01-27 2017-10-19 Neuren Pharmaceuticals Ltd Tratamento de perturbações do espetro do autismo utilizando o ácido glicil-l-2-metilpropil-l-glutâmico
WO2014130691A2 (en) * 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
JP6574769B2 (ja) * 2013-07-25 2019-09-11 ニューレン ファーマシューティカルズ リミテッド 二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Also Published As

Publication number Publication date
MX2022004785A (es) 2022-05-16
JP2025148461A (ja) 2025-10-07
WO2021086892A1 (en) 2021-05-06
AU2020376801A1 (en) 2022-06-09
CO2022007501A2 (es) 2022-08-30
US20220339138A1 (en) 2022-10-27
CN115335071A (zh) 2022-11-11
IL292617B1 (en) 2025-11-01
EP4051308A4 (en) 2023-08-23
KR20220106982A (ko) 2022-08-01
EP4051308A1 (en) 2022-09-07
CA3156680A1 (en) 2021-05-06
IL292617A (en) 2022-07-01
JP2022553888A (ja) 2022-12-26
TW202116300A (zh) 2021-05-01
BR112022008095A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
CO2021015318A2 (es) Compuestos y métodos para el tratamiento de covid-19
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX388408B (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CY1120906T1 (el) Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου
AR103118A1 (es) Tratamientos médicos basados en anamorelina
CL2022001079A1 (es) Métodos y composiciones para el tratamiento del síndrome de rett
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.